Your Search Returned 18 tagged news reports
The researchers pointed out that the nanoscale sensors can be particularly useful for making drugs more safely and efficiently, which are based on antibodies. Leveraging these sensors, the engineers characterized variations in the binding power of
In a first, a US patent has been awarded to Serum Institute of India and the University of Pune (UoP) for using a herb used in Ayurvedic medicine, Ashwagandha, as a vaccine adjuvant...Researchers isolated active compounds from the herb that is
As part of the alliance, the companies will employ their respective technologies to constitute diverse lantipeptide-based libraries. Under the alliance, MorphoSys will also license the LanthioPep technology for drug discovery, invest in Lanthio
LDI/Rockland collaboration to the global research community."
The AbSolute High Cap is based on modified silica and will capture both monoclonal and polyclonal antibodies from high titer and large volume feedstock. According to the company, AbSolute High Cap will enable biopharmaceutical firms to minimise the
Defense Department is funding a Pennsylvania biopharmaceutical company to support development of therapeutic antibodies against bio-warfare agents. Morphotek, Inc., a subsidiary of Eisai Inc., said the grant to support the continued development of
ProtevoBio have formed a collaborative research agreement (CRA) to design and construct three biobetter therapeutic monoclonal antibodies (MAbs). Ben du Pont's yet2ventures.com), uses proprietary in silico algorithms to develop various monoclonal
Seattle's Infectious Disease Research Institute has been funded to develop a single-dose influenza vaccine in case of pandemic flu outbreak. The money for research was given by the Defense Advanced Research Projects Agency and the U.S.
Epitomics has completed the first phase of the project to generate and affinity purify rabbit polyclonal antibodies against these biomarkers. The current project is the continuation into Phase II which involves developing rabbit monoclonal antibodies
Sequenta Inc., a molecular diagnostics platform company focused on immune system profiling, said Wednesday it raised $13 million in a second round of funding. The round was led by a consortium including venture funds Switzerland-based Index Ventures